Ocugen was originally established in 2011 as a joint venture between Punch Biotech and Bharat Biotech. During its initial years, Ocugen worked to develop a platform that focused on discovering and developing innovative therapeutic approaches for the treatment of a range of retinal diseases. This platform culminated in Ocugen's launch of the RNAi-based therapy Ocumination in July 2016.
